MECHANISM OF ACTION AND ADVERSE REACTIONS OF ANTIVIRALS RECOMMENDED FOR HEPATITIS C IN BRAZIL

Abstract

Hepatitis C is a disease that affects the entire world population, also affecting the population’s quality of life. The use of medications is  fundamental for the therapeutic process of patients with hepatitis C. The  treatment of hepatitis C faced several obstacles with the viral pangenotypic  diversity and the adverse treatment reactions faced by those infected with  the vírus. However, over the years, the evolution of the pharmaceutical  market and antiviral drugs has occurred in several research fields against  hepatitis C. In this context, it is important to understand the mechanisms of  action and adverse reactions of the drugs used to treat hepatitis C in Brazil.  The research is a bibliographic review, through a survey of scientific articles  in the databases LILACs, Pubmed, Google Acadêmico, and SciELO, ordinances, and bulletins from the Ministry of Health. Molecular  improvements of the drugs aim to decrease the treatment time, thus  increasing patient compliance because these new drugs have mild adverse  effects. Concerning the treatment of hepatitis C, the pharmaceutical industry trend is to produce pangenotypic drugs, that is, that act in all HCV genotypes.